10-Q: Milestone Pharma Launches CARDAMYST, Advances AFib-RVR Trials

Milestone Pharmaceuticals Inc. reports on the commercial launch of CARDAMYST, progress in its AFib-RVR clinical program, and financial updates for the quarter ended June 30, 2026.

Summary

• Milestone Pharmaceuticals Inc. has launched CARDAMYST (etripamil) nasal spray in the U.S. for paroxysmal supraventricular tachycardia (PSVT), generating initial product revenues.
• The company is advancing its Phase 3 clinical program for etripamil in atrial fibrillation with rapid ventricular rate (AFib-RVR), with first patient enrollment expected in the second half of 2026.
• Financially, the company reported $0.6 million in product revenue for the three months ended June 30, 2026, and a net loss of $28.6 million for the same period.
• As of June 30, 2026, Milestone had $170.6 million in cash, cash equivalents, and short-term investments, which management believes is sufficient for at least the next 12 months.
• A third amendment to the Note Purchase Agreement was executed on June 29, 2026, extending the company's option to defer interest payments to March 31, 2027.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this filing as moderately positive, reflecting the commercial launch of CARDAMYST and progress in clinical development, balanced by ongoing operational losses and the need for future financing.

Positives

• Successful commercial launch of CARDAMYST (etripamil) nasal spray in the U.S. for PSVT.
• Initiation of shipments and generation of initial product revenues ($0.6 million for Q2 2026).
• Advancement of the Phase 3 registrational program for etripamil in AFib-RVR, with site onboarding underway.
• FDA approval for CARDAMYST received on December 12, 2025.
• Sufficient cash reserves ($170.6 million) to fund operations for at least the next 12 months.
• Positive Phase 2 data from the ReVeRA study for etripamil in AFib-RVR presented and published.
• Amendment to the Note Purchase Agreement extends interest deferral option to March 31, 2027, providing financial flexibility.

Negatives

• Significant net loss of $28.6 million for the three months ended June 30, 2026, and $54.7 million for the six months ended June 30, 2026.
• Accumulated deficit of $485.3 million as of June 30, 2026.
• Continued reliance on external financing to fund operations and development.
• Low initial product revenue ($0.6 million for Q2 2026) compared to operating expenses.
• The company is in the initial stages of launch and expects operating losses and negative cash flows to continue for the foreseeable future.

Risks

• The company is subject to risks associated with commercializing CARDAMYST, including market acceptance and competition.
• Reliance on a single source manufacturer for critical components and finished product.
• Uncertainty of clinical trial success for etripamil in AFib-RVR and other indications.
• Potential for delays or problems in the supply chain or manufacturing processes.
• The need for additional financing, and the uncertainty of its availability on acceptable terms.
• The company may be impacted by general economic, political, and market conditions, including inflation and interest rate fluctuations.
• Intellectual property protection and potential disputes.

Future Outlook

The company expects to continue incurring significant expenses and operating losses for the foreseeable future, with a substantial portion of capital resources focused on CARDAMYST commercialization and the development of additional etripamil indications. Management believes current cash reserves are sufficient for at least the next 12 months, but future operations may require additional equity or debt financing.

Management Comments

• "We believe that PSVT is a large and under-recognized market which we estimate affects more than two million Americans."
• "We believe that etripamil has the potential to help people experiencing a symptomatic episode of AFib-RVR to self-treat and to conveniently, reliably, and quickly reduce their elevated heart rate, with the goal of reducing the need for emergency department utilization."
• "We expect our future commercial expenses will increase as we invest in the infrastructure, personnel, and operational expenses required to commercialize CARDAMYST in the United States."
• "We believe that our cash, cash equivalents, and short-term investments as of June 30, 2026, will be sufficient to fund our planned operations for at least the next 12 months from the date of issuance of these unaudited interim condensed consolidated financial statements."

Industry Context

StockSavvy.ai notes that Milestone Pharmaceuticals is operating in the highly competitive biopharmaceutical sector, focusing on cardiovascular treatments. The commercial launch of CARDAMYST addresses a significant unmet need in PSVT treatment, moving towards patient-administered therapies. The development for AFib-RVR also targets a large patient population with limited self-treatment options, aligning with industry trends towards decentralized and patient-centric care.

Comparison to Industry Standards

• The commercialization strategy for CARDAMYST, focusing on patient self-administration for acute conditions like PSVT, aligns with a broader industry trend towards empowering patients and reducing reliance on emergency department visits for immediate symptom relief.
• The development of etripamil for AFib-RVR follows a similar path, aiming to provide a convenient, rapid-onset treatment option for a common and symptomatic complication of atrial fibrillation, a condition affecting millions globally.
• The company's reliance on clinical trial data and regulatory pathways (e.g., sNDA for AFib-RVR leveraging PSVT approval) is standard practice in the pharmaceutical industry for seeking new indications.
• The financial performance, characterized by significant R&D investment and operating losses offset by initial product revenue, is typical for a biopharmaceutical company in the commercialization phase, prior to achieving profitability.

Legal Proceedings

• The company is not currently a party to any material legal proceedings and is not aware of any pending or threatened legal proceeding that could have an adverse effect on its business.

Related Party Transactions

• The company entered into a Note Purchase Agreement with RTW Investments LP and certain of its affiliates, which was amended on June 29, 2026.
• RTW Royalty I DAC, an affiliate of RTW, purchased the right to receive tiered quarterly royalty payments on net product sales of CARDAMYST in the U.S. for $75.0 million.

Stakeholder Impact

• Shareholders may experience dilution from potential future equity financing.
• Patients with PSVT may benefit from the new self-administered treatment option.
• Patients with AFib-RVR may benefit from the potential future availability of etripamil as a self-administered treatment.
• Creditors and debt holders are subject to the company's financial performance and ability to service debt, including the convertible notes and royalty financing obligation.

Next Steps

• Continue commercialization of CARDAMYST in the United States.
• Enroll the first patient in the Phase 3 AFib-RVR trial in the second half of 2026.
• Seek marketing approval for etripamil from regulatory agencies outside the U.S. for PSVT.
• Continue to invest in infrastructure, personnel, and operational expenses for commercialization and R&D.
• Explore potential collaborations for development and commercialization in regions outside Greater China.

Key Dates

Recommendation

The company has achieved a significant milestone with the commercial launch of CARDAMYST and is progressing its pipeline. However, the substantial ongoing losses, reliance on future financing, and the early stage of commercial revenue generation warrant a cautious 'hold' rating. Investors should monitor revenue growth, clinical trial progress for AFib-RVR, and the company's ability to secure necessary funding.

Keywords

etripamil, CARDAMYST, PSVT, AFib-RVR, nasal spray, cardiovascular, biopharmaceutical, clinical trials